Consensual guidelines of the Czech National Haemophilia Programme (CNHP) for the diagnosis and treatment of patients with congenital haemophilia and FVIII/ FIX inhibitors
Authors:
Pracovní Skupina Čnhp Pro Standardy:; E. Zápotocká 1; J. Blatný 2; P. Smejkal 3; Rady Koordinační Jménem; Výkonné Rady Čnhp:; B. Blažek 4; Z. Čermáková 5; Z. Černá 6; P. Ďulíček 7; Z. Hajšmanová 8; J. Hak 9; A. Hluší 10; R. Hrdličková 5; V. Komrska 1; P. Ovesná 11; M. Penka 3; D. Pospíšilová 12; D. Procházková 13; P. Timr 14; J. Ullrychová 15; I. Vonke 16; L. Walterová 17
Authors‘ workplace:
Klinika dětské hematologie a onkologie FN Motol, Praha
1; Oddělení dětské hematologie, FN Brno
2; Oddělení klinické hematologie, FN Brno
3; Klinika dětského lékařství FN Ostrava
4; Klinika hematoonkologie a Krevní centrum, FN Ostrava
5; Dětská klinika FN Plzeň
6; IV. interní hematologická klinika FN Hradec Králové
7; Ústav klinické bio chemie a hematologie, FN Plzeň
8; Dětská klinika FN Hradec Králové
9; Hemato-onkologická klinika FN Olomouc
10; Institut bio statistiky a analýz, LF MU, Brno
11; Dětská klinika FN Olomouc
12; Dětská klinika Krajské zdravotní a. s., Masarykovy nemocnice v Ústí nad Labem
13; Dětské oddělení, Nemocnice České Budějovice
14; Oddělení klinické hematologie, Krajská zdravotní a. s., Masarykova nemocnice v Ústí nad Labem
15; Oddělení klinické hematologie, Nemocnice České Budějovice
16; Oddělení klinické hematologie, Krajská nemocnice Liberec
17
Published in:
Transfuze Hematol. dnes,27, 2021, No. 2, p. 173-184.
Category:
doi:
https://doi.org/10.48095/cctahd2021173
Overview
The aim of these guidelines is to set-up and standardize diagnostic as well as therapeutic approaches to patients suffering from congenital haemophilia and factor VIII or factor IX inhibitors. Update of the original consensual guidelines is based on evolution in our experience and reflects new available data as well as the advent of new drugs revolutionising our therapeutic approach.
Keywords:
haemophilia – guidelines – treatment – inhibitor – surgery
Sources
1. Astermark J. FVIII inhibitors: pathogenesis and avoidance. Blood. 2015;125:2045–2051.
2. Kasper C, Aledort L, Counts R, et al. A more uniform measurement of factor VIII inhibitors. Thrombos Diathes Haemorrh. 1975;34:869–872.
3. White GC, Rozendal F, Aledort L, et al. Definitions in hemophilia. Thromb Haemost. 2001;85:560.
4. Kasper C. Human factor VIII for bleeding in patients with inhibitors. Vox Sang. 1999;77(Suppl 1):47–48.
5. Peyvandi F, Mannucci PM, Garagiola I, et al. A randomized trial fo factor VIII and neutralizing antibodies in hemophilia A. N Eng J Med. 2016;374:2054–2064.
6. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia. 2003;9:418–435.
7. Gouw SC, vand der Bom JG, Ljung R, et al. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med. 2013;368:231–239.
8. DiMichele DM, Hoots WK, Pipe SW, et al. International workshop on immune tolerance induction: consensus recommendations. Haemophilia. 2007;13(Suppl. 1):1–22.
9. Male Ch, Andersson NG, Rafowicz A, et al. Inhibitor incidence in an unselected cohort of previously untreated patiens with severe haemophilia B: A PedNet Study. Haematologica. 2021;106(1):123–129.
10. Blatný J, Komrska V, Blazek B, et al. Inhibitor’s incidence rate in Czech previously untreated patients with haemophilia A has not increased since introduction of recombinant factor VIII treatment in 2003. Blood Coag Fibrinolysis. 2015;26:673–678.
11. Darby SC, Keeling DM, Spooner RJD, et al. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99. J Thromb Haemost. 2004;2:1047–1054.
12. Eckhardt CL, van Velzen AS, Peters M, et al. Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. Blood. 2013;122:1954–1962.
13. Van den Berg, Fischer K, Carcao M, et al. Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A. Blood. 2019;134:317–320.
14. Hay CRM. The epidemiology of factor VIII inhibitors. Haemophilia. 2006;12(Suppl. 6):23–29.
15. Gouw SC, van der Bom JG, van den Berg HM. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood. 2007;109:4648–4654.
16. Calvez T, Chambost H,Claeyssens-Donadel S, et al. Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A. Blood. 2014;124(23):3398–3408.
17. Fischer K, Lassila R, Peyvandi F, et al. Inhibitor development in haemophilia according to concentrate. Four-year results from the European HAemophila Safety Surveilance (EUHASS) project. Thromb Haemost. 2015;113:968–975.
18. Hassan S, Cannavo A, Gouw SC, et al. Factor VIII products and inhibitor development in previously treated patients with severe or moderately severe hemophilia A: a systematic review. J Thromb Haemost. 2018;16:1055–1106.
19. Giles AR, Verbruggen B, Rivard GE, et al. A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada. Thromb Haemost. 1998;79:872–875.
20. DiMichele D. Inhibitor treatment in haemophilias A and B: inhibitor diagnosis. Haemophilia. 2006;12(Suppl. 6):37–42.
21. Verbruggen B, Novakova I, Wessels H, et al. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitor. Improved specifity and reliability. Thromb Haemost. 1995;73:247–251.
22. Giangrande PLF, Hermans C, O’Mahony B, et al. European principles of inhibitor management in patiens with haemophilia. Orphanet J Rare Dis. 2018;13:66.
23. Collins PW, Chlamers E, Hart DP, et al. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). Br J Haematol. 2013;160:153–170.
24. Collins PW, Chlamers E, Chowdary P, et al. The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO. Haemophilia. 2016;22:487–498.
25. Astermark J, Altisent C, Batorova A, et al. Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report. Haemophilia. 2010;16:747–766.
26. Oldenburg J, Pavlova A. Genetic risk factors for inhibitors to factors VIII and IX. Haemophilia. 2006;12(Suppl. 6):15–22.
27. Gouw SC, van der Born JG, Auerswald G, et al. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood. 2007;109:4693–4697.
28. Fischer K, Collins PW, Ozelo MC, et al. When and how to start prophylaxis in boys with severe hemophilia without inhibitors: Communication from SSc of the ISTH. J Thromb Haemost. 2016;14:1105–1109.
29. Feldman BM, Rivard GE, Babyn P, et al. Tailored frequency-escalated primary prophylaxis for severe haemophilia A: results of the 16-years Canadina Hemophilia Prophylaxis Study longitudinal kohort. Lancet Haematol. 2018;5:e252–e260.
30. Eckhardt CL, Menke LA, van Ommen CH, et al. Intensive peri-operative use of factor VIII and the Arg593 ® Cys station are risk factors for inhibitor development in mild/ moderate hemophilia A. J Thromb Haemost. 2009;7:930–937.
31. Chalmers EA, Brown SA, Keeling D, et al. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A. Haemophilia. 2007;13:149–155.
32. Mancuso ME, Mannucci PM, Rocino A, et al. Source and purity of factor VIII producst as risk factors for inhibitor development in patiens with hemophilia A. J Thromb Haemost. 2012;10:781–790.
33. Franchini M, Tagliaferri A, Mengoli C, Cruciani M. Cumulative inhibitor incidence in previously untreated patient with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: A critical systemic review. Crit Rev Oncol Hematol. 2012;8:82–93.
34. Königs C., Ozelo MC, Dunn A, et al. Final results of PUPs A-LONG Study: evaluating safety and efficacy of rFVIIIFc in previously untreated patients with haemophilia A. [abstract] Res Pract Thromb Haemost. 2020;4(Suppl 1). https:/ / abstracts.isth.org/ abstract/ final-results-of-pups-a-long-study-evaluating-safetz-and-efficacy-of-rfviiifc-in-previously-untreated-patients-with-haemophilia-a./ accessed September 2.2020
35. Le Quellec S. Clinical evidence and safety profile of emicizumab for the management of children with hemophilia A. Drug Des Devel Ther. 2020;14:469–481.
36. Jones ML, Wight J, Paisley S, Knight C. Control of bleeding in patients with haemophilia A with inhibitors: a systematic review. Haemophilia. 2003;9:464–520.
37. Srivastava A, Santangostino E, Dougall A, et al. WFH Guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26(S6): 1–158.
38. Teitel J, Berntorp E, Collins P, et al. A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors. Haemophilia. 2007;13:256–263.
39. Astermark J, Rocino A, von Depka M, et al. Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors. Haemophilia. 2007;13:38–45.
40. Santagostino E, Escobar M, Ozelo M, et al. Recombinant activated FVII in the treatment of bleeds and for the prevention of surgery-related bleeding in congenital haemophilia with inhibitors. Blood Rev. 2015;29(Suppl 1):S9–S18.
41. Santagostino E, Mancuso ME, Rocino A, et al. A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors. J Thromb Haemost. 2006;4:367–371.
42. Young G, Shafer FE, Roja P, et al. Single 270 ug/ kg dose rFVIIa vs standard 90 ug/ kg dose rFVIIa and APCC for home treatment of joing bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia. 2008;14:287–294.
43. Morfini M, Auerswald G, Kobelt RA, et al. Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres. Haemophilia. 2007;13:502–507.
44. Konkle BA, Ebbesen LS, Erhardtsen E et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost. 2007;5:1904–1913.
45. Young G, McDaniel M, Nugent DJ. Prophylactic recombinant factor VIIa in haemophilia patients with inhibitors. Haemophilia. 2005;11:203–207.
46. López-Fernández MF, Roca CA, Alvarez-Román MT, et al. Spanish consensus guidelines on prophylaxis with bypassing agents in patients with haemophilia and inhibitors. Thromb Haemost. 2016;115:872–895.
47. Mingot-Castellano ME, Alvarez-Román MT, López-Fernández MF, et al. Spanish consensus guidelines on prophylaxis with bypassing agents for surgery in patients with haemophilia and inhibitors. Eur J Haematol. 2016;96:461–474.
48. Valentino LA, Cooper DL, Goldstein B. Surgical experience with rVIIa (NovoSeven) in congenital haemophilia A nad B patiens with inhibitors to factors VIII or IX. Haemophilia. 2011;17:579–589.
49. Castaman G. The role of recombinant activated factro VII in the haematological management of elective orthopaedic surgery in haemophilia A patients with inhibitors. Blood Transfus. 2017;15:478–486.
50. Rodriguez-Merchan EC, Rocino A, Ewenstein B, et al. Consensus perspectives on surgery in haemophilia patients with inhibitors: summary statement. Haemophilia. 2004;10(Suppl. 2):50–52.
51. Giangrande PLF, Wilde JT, Madan B, et al. Consensus protocol for the use of recombinant activated factor VII (eptacog alfa (activated); NovoSeven) in elective orthopaedic surgery in haemophilic patients with inhibitors. Haemophilia. 2009;15:501–508.
52. Kulkarni R. Comprehensive care of the patient with haemophilia and inhibitors undergoing surgery: practical aspects. Haemophilia. 2013;19:2–10.
53. Rajpurkar R, Cooper DL. Continuous infusion of recombinant activated factor VII: a review of data in congenital hemophilia with inhibitors and congenital factor VII deficiency. J Blood Medic. 2018;9:227–239.
54. Negrier C, Gomperts ED, Oldenburg J. The history of FEIBA: a lifetime of success in the treatment of haemophilia complicated by an inhibitor. Haemophilia. 2006;12(Suppl. 5):4–13.
55. Tran HTT, Sorensen B, Rea CJ, et al. Tranexamic acid as adjunct therapy to bypassing agents in haemophilia A patients with inhibitors. Haemophilia. 2014;20:369–375.
56. Valentino LA, Holme PA. Should anti-inhibitor coagulant complex and treanexamic acid be used concomitantly? Haemophilia. 2015;21:709–714.
57. Rangarajan S, Austin S, Goddard NJ, et al. Consensus recommendation for the use of FEIBA® in haemophilia A patiens with inhibitors undergoing elective orthopaedic and non-orthopaedic surgery. Haemophilia. 2013;19:294–303.
58. Stasyshyn O, Antunes S, Mamonov V, et al. Prophylaxis with anti-inhibitor coagulant complex improves health related quality of life in haemophilia patients with inhibitors: results from FEIBA NF Prophylaxis study. Haemophilia. 2014;20:644–650.
59. DiMichele D, NEgrier C. A retrospective postlicentsure survery of FEIBA efficacy and safety. Haemophilia. 2006;12:352–362.
60. Young G, Cooper DL, Gut RZ: Dosing and effectiveness of recombinant activated factor VII (rFVIIA) in congenital haemophilia with inhibitors by bleed type and location: the experience of the Haemophilia and Thrombosis Research Society (HTRS) Registry (2004-2008). Haemophilia. 2012;18:990–996.
61. Chambost H, Santagostino E, Laffan M, et al. Real-world outcomes with recombinant factor VIIa treatment of acute bleeds in haemophilia patients with inhibitors: results from the international ONE registry. Haemophilia. 2013;571–577.
62. Astermark J, Donfield SM, DiMichele DM, et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood. 2007;109:546–551.
63. Matino D, Makris M, Dwan K, et al. Recombinatn factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemohilia and inhibitors. Cochrane Dat Syst Rev. 2015;CD004449.
64. Schneiderman J, Rubin E, Nugent DJ, Zouny G. Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patiens with severe haemophilia and inhibitors: update of our previous experience. Haemophilia. 2007;13:244–248.
65. Gomperts ED, Astenmark J, Gringeri A, Teitel J. From theory to practice: applying current clinical knowledge and treatment strategies to the care of hemophilia A patients with inhibitors. Blood Rev. 2008;22(Suppl. 1):1–11.
66. Gringeri A, Fischer K, Karafoulidou A, et al. Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors. Haemophilia. 2011;17: 630–635.
67. Martinowitz U, Livnat T, Zivelin A, et al. Concomitant infusion of low doses of rFVIIa and FEIBA in haemophilia patients with inhibitors. Haemophilia. 2009;15:904–910.
68. Mancuso ME, Fasulo MR. Thrombin generation assay as a laboratory monitoring tool during bypassing therapy in patients with hemophilia and inhibitors. Semin Thromb Hemost. 2016;42:30–35.
69. Dargaud Y, Sorensen B, Shima M, et al. Global haemostasis and point of care testing. Haemophilia. 2012;18(Suppl. 4):81–88.
70. Freiburghaus C, Berntorp E, Ekman M, et al. Immunoadsorption for removal of inhibitors: update on treatments in Malmö-Lund between 1980 and 1995. Haemophilia. 1998;4:16–20.
71. Nilsson IM, Berntorp E, Freiburghaus Ch. Treatment of patiens with factor VIII and IX inhibitors. Thromb Haemost. 1993;70(1):56–59.
72. Young G, Auerswald G, Jimenez-Yuste V, et al. When should prophylaxis therapy in inhibitor patients be consider? Haemophilia. 2011;17:e849–e857.
73. Antunes SV, Tangada S, Stasyshyn O, et al. Randomized comparison of propfylaxis and on-demand regres FEIBA NF in the treatment of haemopgilia A and B with inhibitor. Haemophilia. 2014;20:65–72.
74. Shima M, Hanabusa H, Taki M, et al. Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A. N Engl J Med. 2016;374:2044–2053.
75. Arruda VR, Doshi BS, Samelson-Jones BJ. Novel approaches to hemophilia therapy: successes and challenges. Blood. 2017;130:2251–2256.
76. Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377:809–818.
77. Young G, Liesner R, Chang T, et al. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia Awith inhibitors. Blood. 2019;134:2127–2138.
78. Collins PW, Liesner R, Makris M, et al. Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving emicizumab. Interim guidance from UKHCDO inhibitor working party and executive committee. Haemophilia. 2018;24: 344–347.
79. Castaman G, Santoro C, Coppola A, et al. Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab. Blood Transf. 2020;18:143–151.
80. Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med. 2017;377:809–818.
81. Pipe SW, Shima M, Lehle M, et al. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A / HAVEN4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol. 2019;6:e295–e305.
82. Gundabolu K, Goldweig A, Bhatt VR, et al. STsegment elevation myocardial inferction and pulmonary embolism in a hemophilia A patient receiving emicizumab and recombinant activated factor VII. Haemophilia. 2020;26:e5-e8.: 111–122.
83. Santagostino E, Oldenburg J, Chang T, et al. Surgical experience from four phase III studies (HAVEN 1-4) of emicizuumab in persons with haemophilia A (PwHAú with or without FVIII inhibitors. Rec Pract Thromb Haemost. 2019;3(S1):115.
84. Santagostino E, Mancuso ME, Novembrino C, et al. Rescue factor VIII replacement to secure hemostasis in a patient with hemophilia A and inhibitors on emicizumab prophylaxis undergoing hip replacement. Haematologica. 2019;104:e380–e382.
85. Ljung R, Auerswald G, Benson G, Dolan G, Duffy A, et al. Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficul-to-treat patients. Eur J Haematol. 2019;102:111–122.
86. Hay CRM, Recht M, Carcao M, Reipert B. Current and Future Approaches to Inhibitor Management and Aversion. Semin Tromb Hemost. 2006;32(Suppl. 2):15–21.
87. Nakar C, Manco-Johnson MU, Lail A, et al. Prompt immune tolerance induction at inhibitor diagnosis regardless of titre may increase overal success in haemophilia A complicated by inhibitors: experience of two U.S. centres. Haemophilia. 2015;21:365–373.
88. Carcao M, Shapiro A, Staber JM, et al. Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A with inhibitors – A retrospective analysis. Haemophilia. 2018;24:245–252.
89. Astermakr J, Morado M, Rocino A, et al. Current European practise in immune tolerance induction therapy in patients with haemophilia and inhibitors. Haemophilia. 2006;12:363–371.
90. Hay CRM, DiMichele DM. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood. 2012;119:1335–1344.
91. Wight J, Paisley S, Knight C. Immune tolerance induction in patiens with haemophilia with inhibitors: a systematic review. Haemophilia. 2003;9:436–463.
92. Brackmann HH, Oldenburg J, Schwaab R. Immune tolerance for the treatment of factor VIII inhibitors-twenty years „bonn protocol“. Vox Sang. 1997;70:30–35.
93. UKHCDO protocol for first line immune tolerance induction for children with severe haemophilia A: A protocol from the UKHCDO Inhibitor and Paediatric Working Parties ze dne 1.2.2017 – dostupné na: http:/ / www.ukhcdo.org/ wp-content/ uploads/ 2017/ 01/ ITI-protocol-2017.pdf.
94. Kreuz W, Escuriola Ettingshausen C, Vdovin V, et al. First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/ von Willebrand factor concentrate in an onservational immune tolerance induction study. Haemophilia. 2016;22:87–95.
95. Carcao M, Escuriola Ettingshausen C, Santagostino E, et al. The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab. Haemophilia. 2019;25:676–684.
96. Batsuli G, Zimowski KL, Tickle K, et al. Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis. Haemophilia. 2019;25:789–796.
97. Lim MY, Nielsen B, Lee K, et al. Rituxibam as first-line treatment for the management of adult patients with non-severe hemophilia A and inhibitors. J Thromb Haemost. 2014;12:897–901.
98. Holstein K, Batorova A, Carvalho M, et al. Current view and outcome of ITI therapy – a change over time? Thromb Res. 2016;148:38–44.
99. Young G. Emplementing emicizuman in hemophilia inhibitor management: emicizumab should be prescribed after tolerance. Blood Adv. 2018;2:2780–2782.
100. Van Velzen AS, Eckhardt CL, Hart DP, et al. Inhibitors in nonsevere haemophilia A: outcome and eradication strategies. Thromb Haemost. 2015;114:46–55.
101. Beutel K, Hauch HF, Rischewski JF, et al. ITI with high‐dose FIX and combined immuno‐ suppressive therapy in a patient with severe haemophilia B and inhibitor. Hamostaseologie. 2009;29:155–157.
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2021 Issue 2
Most read in this issue
- Transfusion related acute lung injury (TRALI) prevention – selection of donors for producing plasma designated for clinical use
- A peripherally inserted central catheter is a safe means of ensuring long-term central venous access in patients with acute leukaemia – a single centre experience
- Mucormycosis – review of literature and case report
- Changes in the immune system of untreated patients with chronic lymphocytic leukaemia – part 1: adaptive immunity